RET fusion

RET gene fusions detected by sequencing or FISH; used as a predictive marker for selective RET inhibitors in non-small cell lung, thyroid and other solid tumors.

CI-BIO-00000022RET graph →NCIt C131069 Tumor-agnostic · 3 approval rows

Also calledRET rearrangement · RET fusion-positive · KIF5B-RET · CCDC6-RET

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (3)

Selpercatinib EU EMA · Feb 11, 2021 · drug in derived setRegulatory approved
Selpercatinib US FDA · Apr 10, 2024 · drug + indication textRegulatory approved
Selpercatinib US FDA · May 8, 2020 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (10)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Thyroid Gland Medullary Carcinoma	15	13	2	—	3 / 6 / 3 / 3 / 0
Lung Non-Small Cell Carcinoma	8	8	—	—	1 / 4 / 3 / 0 / 0
Lung Adenocarcinoma	4	3

Derived

Drugs with predictive evidence (12)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
SelpercatinibSmall Molecule	18	16	2	A	19 / 6	Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Malignant Thyroid Gland Neoplasm, Solid Neoplasm +2
VandetanibSmall Molecule	5	5	—	B	5 / 0	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Breast Neoplasm
PralsetinibSmall Molecule	3	3	—	A	3 / 0	Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Malignant Thyroid Gland Neoplasm
CabozantinibSmall Molecule	2	2	—	B	2 / 0	Lung Adenocarcinoma, Thyroid Gland Medullary Carcinoma
MotesanibSmall Molecule	2	—	2	D	0 / 2	Thyroid Gland Medullary Carcinoma
AgerafenibSmall Molecule	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
AlectinibSmall Molecule	1	1	—	C	1 / 0	Lung Non-Small Cell Carcinoma
EverolimusSmall Molecule	1	1	—	C	1 / 0	Lung Adenocarcinoma
JAK2 Inhibitor AZD1480	1	1	—	D	1 / 0	Thyroid Gland Medullary Carcinoma
NintedanibSmall Molecule	1	1	—	C	1 / 0	Lung Non-Small Cell Carcinoma
SorafenibSmall Molecule	1	1	—	B	1 / 0	Thyroid Gland Medullary Carcinoma
SunitinibSmall Molecule	1	1	—	C	1 / 0	Papillary Adenocarcinoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (35)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–35 of 35 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RET Fusion10
Cabozantinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID4847 RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with … (full text at CIViC) PMID 27825636 · Drilon et al., 2016 · Open in CIViC	civic
Alectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID4850 Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had receive… (full text at CIViC) PMID 27544060 · Lin et al., 2016 · Open in CIViC	civic
Pralsetinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID11233 In an open-label, phase 1/2 trial on 87 patients with NSCLC including RET-fusion were given 400 mg once-daily oral pralsetinib, with the outcome measured as overall response rate. Overall responses we… (full text at CIViC) PMID 34118197 · Gainor et al., 2021 · Open in CIViC	civic
Selpercatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID7066 In this phase 1 trial, 57 patients with RET fusion- or mutation positive cancers were treated in 7 dose levels. Among patients with RET-Fusion positive NSCLC, objective response rates were 65% (n = 17… (full text at CIViC) Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID8850 Patients with RET-fusion positive non-small cell lung cancer were enrolled in this phase 1-2 trial of RET inhibitor selpercatinib. Among 105 consecutively enrolled patients who had previously received… (full text at CIViC) PMID 32846060 · Drilon et al., 2020 · Open in CIViC	civic
Vandetanib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID4848 RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset. This study was a multi-center, open-label, phase II clinical trial to examine the safety and effi… (full text at CIViC) PMID 27803005 · Lee et al., 2017 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID4849 We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged N… (full text at CIViC) PMID 27825616 · Yoh et al., 2017 · Open in CIViC	civic
Pralsetinib	Malignant Thyroid Gland Neoplasm	Predictive	A	Supports Sensitivity Response	4	accepted	EID11234 In a phase 1/2, open-label trial, 122 patients with RET-mutant medullary cancer and 20 with RET-fusion positive thyroid cancer were administered 400 mg daily oral pralsetinib. The overall response rat… (full text at CIViC) PMID 34118198 · Subbiah et al., 2021 · Open in CIViC	civic
Selpercatinib	Malignant Thyroid Gland Neoplasm	Predictive	A	Supports Sensitivity Response	4	accepted	EID8852 In this phase 1/2 trial (NCT03157128), patients with RET altered thyroid cancers were enrolled to receive the highly selective RET inhibitor selpercatinib. Among 19 patients with previously treated RE… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID7069 In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Among the 6 patients with RET-fusion positive papil… (full text at CIViC) Open in CIViC	civic
RET Fusion2
Everolimus + VandetanibCombination	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1622 Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC) PMID 25982012 · Subbiah et al., 2015 · Open in CIViC	civic
Vandetanib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID698 A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission i… (full text at CIViC) PMID 23584301 · Gautschi et al., 2013 · Open in CIViC	civic
RET Fusion2
Nintedanib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID1601 Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedani… (full text at CIViC) PMID 26787234 · Takeda et al., 2016 · Open in CIViC	civic
Agerafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID7480 A patient with right-sided, MSI-High and CCDC6-RET positive metastatic colorectal cancer showed complete response to the selective RET inhibitor RXDX-105. The patient remained progression-free after 1… (full text at CIViC) PMID 29538669 · Pietrantonio et al., 2018 · Open in CIViC	civic
RET Fusion + RET G810C + RET G810R + RET G810S1
Selpercatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	4	accepted	EID8195 A 61-year old patient with KIF5B-RET fusion positive NSCLC received clinical benefit from selpercatinib treatment initially. ctDNA surveillance showed the emergence of RET G810S 3 months after the sta… (full text at CIViC) PMID 31988000 · Solomon et al., 2020 · Open in CIViC	civic
RET Overexpression2
Vandetanib	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID740 Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandeta… (full text at CIViC) PMID 26686064 · Hatem et al., 2016 · Open in CIViC	civic
Sunitinib	Papillary Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1518 A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment. Tumor sequencing showed increased MAPK activity due to RET over-expressi… (full text at CIViC) PMID 20696054 · Jones et al., 2010 · Open in CIViC	civic
RET M918T7
Pralsetinib + SelpercatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID11867 Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC	civic
Selpercatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID11876 Preclinical data demonstrated Ba/F3 cells transformed with RET p.M918T were sensitive to selpercatinib with an IC50 of 5nM. M918T was included as a positive control for other variants that were being … (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
Cabozantinib
RET C618R1
Selpercatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID11877 Preclinical data demonstrated Ba/F3 cells transformed with RET p.C618R were sensitive to selpercatinib with an IC50 of 3.5nM. PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET Mutation + RET Fusion2
Selpercatinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12056 As part of this trial, 27 pediatric patients (aged 2-20), harbouring, RET-mutant medullary thyroid cancer (MTC, n = 14), RET fusion-positive papillary thyroid cancer (RTC, n=10), or other tumour types… (full text at CIViC) Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID12708 In the phase 1/2 trial LIBRETTO-121 (NCT03899792), for patients 0.5-21 yrs old with advanced RET-altered solid tumors, dosing started at 92 mg/m2 twice a day of Selpercatinib. Patients had RET-mutant… (full text at CIViC) Open in CIViC	civic
RET C634W1
Motesanib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID75 Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET. PMID 21422803 · Coxon et al., 2012 · Open in CIViC	civic
RET Mutation3
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	A	Supports Sensitivity Response	4	accepted	EID8851 In this international phase 1/2 trial (NCT03157128), 55 RET-mutant medullary thyroid cancer patients who had previously received the multi-kinase inhibitors vandetanib and/or cabozantinib received th… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC	civic
〃	Thyroid Gland Medullary CarcinomaALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID12157 In this phase III trial, 291 patients (12 years or older) with medullary thyroid cancer harbouring RET mutations were enrolled. Patients were randomized in a 2:1 ratio to receive selpercatinib (n=193)… (full text at CIViC) PMID 37870969 · Hadoux et al., 2023 · Open in CIViC	civic
〃	Thyroid Gland Medullary Carcinoma
RET E632_L633del1
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID11875 Among 319 medullary thyroid cancer patients enrolled in the LIBRETTO-001 trial, 9 patients harbored the RET p.E632_L633del mutation (c.1894_1899delGAGCTG) in their tumor. After treatment with the sel… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET M918T + RET V804M1
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	4	accepted	EID6950 After progressing on 6 multi-kinase inhibitor (MKI) regimens (including sorafenib , vandetanib, cabozantinib, MGCD-516, RXDX-105, and vandetanib plus everolimus ), a metastatic medullary thyroid cance… (full text at CIViC) PMID 29912274 · Subbiah et al., 2018 · Open in CIViC	civic
RET V804M1
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID7068 In this phase 1 trial, 57 patients were treated with the selective RET Inhibitor selpercatinib (LOXO-292). A 57-year-old male with a hereditary RET V804M gatekeeper mutation treated with 3 prior multi… (full text at CIViC) Open in CIViC	civic
RET G810S + RET M918T1
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Resistance	3	accepted	EID8196 In two out of three patients with MTC treated in a phase1/2 trial, the RET G810 mutation emerged in ctDNA together with an acquired resistance after initial response to selpercatinib. PMID 31988000 · Solomon et al., 2020 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (164)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory14 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Sunitinib	US FDA	—	Efficacy supplement 2011-05-20 (see label)	approved	May 20, 2011	openfda
Sunitinib	US FDA	—	Efficacy supplement 2010-07-01 (see label)	approved	Jul 1, 2010	openfda
Sunitinib	US FDA	—	Efficacy supplement 2007-02-02 (see label)	approved	Feb 2, 2007	openfda
Sunitinib	US FDA	—	Efficacy supplement 2007-02-02 (see label)	approved	Feb 2, 2007

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (78)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 37 recruiting · 16 active phase 3 · 394 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 51–78 of 78 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01674140	S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer(e3)	active not recruiting	Phase 3	1,939	SWOG Cancer Research NetworkNETWORK	2	Feb 10, 2026	clinicaltrials
NCT07024173	A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer	recruiting	Phase 3	240	Shandong Suncadia Medicine Co., Ltd.INDUSTRY	1	Jan 26, 2026	clinicaltrials
NCT03539822	Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA)	recruiting	Phase 1 / Phase 2	117	Anwaar SaeedOTHER	1	Jan 21, 2026	clinicaltrials
NCT05933395	Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor(GERTRUDE)	recruiting	Phase 2	135	Dartmouth-Hitchcock Medical CenterOTHER	1	Jan 20, 2026	clinicaltrials
NCT07002177	A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC	recruiting	Phase 1 / Phase 2	196	Forward Pharmaceuticals Co., Ltd.INDUSTRY	1	Jan 7, 2026	clinicaltrials
NCT03899792	A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121)	active not recruiting	Phase 1 / Phase 2	36	Eli Lilly and CompanyINDUSTRY	11	Jan 6, 2026	clinicaltrials
NCT04204850	Cabozantinib to Treat Recurrent Liver Cancer Post Transplant	recruiting	Phase 2	20	University Health Network, TorontoOTHER	1	Dec 3, 2025	clinicaltrials
NCT05770037	DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE)	recruiting	Phase 2 / Phase 3	30	Cancer Research UKOTHER	1	Nov 24, 2025	clinicaltrials
NCT04185883	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	active not recruiting	Phase 1	610	AmgenINDUSTRY	13	Oct 22, 2025	clinicaltrials
NCT04194944	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer(LIBRETTO-431)	active not recruiting	Phase 3	261	Eli Lilly and CompanyINDUSTRY	26	Oct 21, 2025	clinicaltrials
NCT01896479	A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer(EXAMINER)	active not recruiting	Phase 4	247	ExelixisINDUSTRY	14	Sep 2, 2025	clinicaltrials
NCT03170960	Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	active not recruiting	Phase 1	914	ExelixisINDUSTRY	9	Aug 17, 2025	clinicaltrials
NCT04341181	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling(ProTarget)	recruiting	Phase 2	300	Ulrik LassenOTHER	1	Jul 25, 2025	clinicaltrials
NCT03944772	Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)(ORCHARD)	active not recruiting	Phase 2	247	AstraZenecaINDUSTRY	9	Jan 30, 2025	clinicaltrials
NCT02299999	SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer(SAFIR02_Breast)	active not recruiting	Phase 2	1,460	UNICANCEROTHER	1	Jan 15, 2025	clinicaltrials
NCT05668962	Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	recruiting	Phase 2	30	Massachusetts General HospitalOTHER	1	Dec 12, 2024	clinicaltrials
NCT05293964	Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer	active not recruiting	Phase 1	214	Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY	1	Nov 29, 2024	clinicaltrials
NCT06709274	Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC(MOTION-NSCLC)	not yet recruiting	N/A	342	Guangdong Association of Clinical TrialsOTHER	1	Nov 29, 2024	clinicaltrials
NCT04322890	Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation(PIKACHU)	recruiting	Phase 2	6,000	Hunan Province Tumor HospitalOTHER	1	Oct 22, 2024	clinicaltrials
NCT05594095	SNF Platform Study of HR+/ HER2-advanced Breast Cancer	recruiting	Phase 2	620	Fudan UniversityOTHER	1	Oct 4, 2024	clinicaltrials
NCT05015010	Alectinib in Neo-adjuvant Treatment of Stage III NSCLC(ALNEO)	active not recruiting	Phase 2	33	Gruppo Oncologico Italiano di Ricerca ClinicaOTHER	1	Aug 9, 2024	clinicaltrials
NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer(EROS)	recruiting	—	80	Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER	1	Aug 9, 2024	clinicaltrials
NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE)	recruiting	Phase 2	250	Helsinki University Central HospitalOTHER	1	Jul 15, 2024	clinicaltrials
NCT05525338	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC)	recruiting	Phase 4	196	University Medical Center GroningenOTHER	2	May 13, 2024	clinicaltrials
NCT05859217	A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)(Cabatezo-1)	not yet recruiting	Phase 2	40	Jun Zhang, MD, PhDOTHER	1	May 8, 2024	clinicaltrials
NCT05949541	Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer(BCTOP-L-M01)	recruiting	Phase 2	265	Fudan UniversityOTHER	1	Feb 8, 2024	clinicaltrials
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)(DRUP)	recruiting	Phase 2	1,550	The Netherlands Cancer InstituteOTHER	1	Jan 24, 2024	clinicaltrials
NCT05725200	Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer(EVIDENT)	recruiting	Phase 2	40	Oslo University HospitalOTHER	1	Feb 21, 2023	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (3)

Associated cancers (10)

Drugs with predictive evidence (12)

Predictive evidence items (35)

Approvals mentioning the linked drugs (164)

Active trials (78)

Linked publications (30)